Advanced search
Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 43, 2024 - Issue 2
Submit an article Journal homepage
135
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Bilateral, sequential orbital inflammatory syndrome associated with ruxolitinib

Viren Ranaa Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USA;b Department of Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USACorrespondence[email protected]
View further author information
,
Eric Kima Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USAView further author information
,
Marjorie Murphya Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USA;b Department of Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USAView further author information
&
Philip Rizzutoa Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USA;b Department of Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USAView further author information
Pages 248-252 | Received 09 Jun 2022, Accepted 26 Jul 2022, Published online: 24 Oct 2022

References

  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. doi:10.1056/NEJMoa1110557.
  • Jakafi® (Ruxolitinib) Prescription Medicine. Jakafi® Ruxolitinib (Tablets). https://www.Jakafi.Com/. Accessed May 11, 2022.
  • Gaspari V, Zengarini C, Greco S, Vangeli V, Mastroianni A. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports. Int J Antimicrob Agents. 2020;56(2):106023. doi:10.1016/j.ijantimicag.2020.106023.
  • Saeed I, McLornan D, Harrison CN. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Rev Hematol. 2017;10(7):617–625. doi:10.1080/17474086.2017.1337507.
  • Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402. doi:10.1016/S1473-3099(20)30132-8.
  • Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis: Figure 1. Clin Cancer Res. 2012;18(11):3008–3014. doi:10.1158/1078-0432.CCR-11-3145.
  • LaFave LM, Levine RL. JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci. 2012;33(11):574–582. doi:10.1016/j.tips.2012.08.005.
  • Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15(1):23. doi:10.1186/s12964-017-0177-y.
  • Yeleswaram S, Smith P, Burn T, et al. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clin Immunol. 2020;218:108517. doi:10.1016/j.clim.2020.108517.
  • Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–1810. doi:10.1056/NEJMoa1917635.
  • Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Case Rep. 2014;2014(jun02 1):bcr2014204950–bcr2014204950. doi:10.1136/bcr-2014-204950.
  • Kerget B, Araz O, Ucar EY, Akgun M, Sağlam L. Acute respiratory distress syndrome; a rare complication caused by usage of ruxolitinib. Respir Med Case Rep. 2017;22:243–245. doi:10.1016/j.rmcr.2017.09.003.
  • Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188–1191. doi:10.4065/mcp.2011.0518.
  • Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369(7):681–683. doi:10.1056/NEJMc1302895.
  • Irey EA, Lassiter CM, Brady NJ, et al. JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors. Proc Natl Acad Sci. 2019;116(25):12442–12451. doi:10.1073/pnas.1816410116.
  • Center for Drug Evaluation and Research. FDA approves fedratinib for myelofibrosis. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fedratinib-myelofibrosis. Accessed April 3, 2022.
  • Lee JY, Gallo RA, Vu DM, Anagnostopoulos AG, Rong AJ. Fedratinib-Induced orbital inflammation. Orbit. Published online November 26, 2020:1–4. doi:10.1080/01676830.2020.1852263.
  • Weiss MJ. New insights into erythropoietin and Epoetin Alfa: mechanisms of action, target tissues, and clinical applications. Oncologist. 2003;8(S3):18–29. doi:10.1634/theoncologist.8-suppl_3-18.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.